CIK 0001672619 · Non-accelerated filer
Enliven Therapeutics, Inc.
Sign in to watch- Ticker
- ELVN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 811523849
- Phone
- 650-547-5814
- Business address
- 205 PARK ROAD, BURLINGAME, CA, 94010
- Former names
- IMARA Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $2,230,845
- in 7 filings, $1.6M under 10b5-1 plans
Net −$2,230,845. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 37 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-08-27 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Option exercise 10b5-1 | +3,250 | $2.48 | $8K | 26,250 |
| 2025-08-27 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −3,250 | $20.63 | $67K | 23,000 |
| 2025-08-27 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Option exercise · Stock Option (right to buy) 10b5-1 | −3,250 | 108,306 | ||
| 2025-08-21 | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | Sale 10b5-1 | −7,500 | $20.01 | $150K | 940,188 |
| 2025-08-20 | Kintz Samuel PRESIDENT AND CEO | Sale 10b5-1 | −1,517 | $20.00 | $30K | 927,892 |
| 2025-08-19 | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | Sale 10b5-1 | −5,000 | $19.62 | $98K | 947,688 |
| 2025-08-19 | Kintz Samuel PRESIDENT AND CEO | Sale 10b5-1 | −590 | $20.00 | $12K | 929,409 |
| 2025-08-18 | Kintz Samuel PRESIDENT AND CEO | Sale 10b5-1 | −10,393 | $20.02 | $208K | 929,999 |
| 2025-08-07 | Patel Anish CHIEF OPERATING OFFICER | Sale 10b5-1 | −6,262 | $18.20 | $114K | 290,380 |
| 2025-08-07 | Patel Anish CHIEF OPERATING OFFICER | Sale 10b5-1 | −405 | $18.93 | $8K | 289,975 |
| 2025-07-28 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Option exercise 10b5-1 | +3,250 | $2.48 | $8K | 26,250 |
| 2025-07-28 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −3,185 | $20.45 | $65K | 23,065 |
| 2025-07-28 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −65 | $21.30 | $1K | 23,000 |
| 2025-07-28 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Option exercise · Stock Option (right to buy) 10b5-1 | −3,250 | 111,556 | ||
| 2025-07-21 | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | Sale 10b5-1 | −11,924 | $22.26 | $265K | 953,264 |
| 2025-07-21 | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | Sale 10b5-1 | −576 | $22.90 | $13K | 952,688 |
| 2025-07-17 | Kintz Samuel PRESIDENT AND CEO | Sale 10b5-1 | −4,150 | $21.58 | $90K | 948,742 |
| 2025-07-17 | Kintz Samuel PRESIDENT AND CEO | Sale 10b5-1 | −4,687 | $22.69 | $106K | 944,055 |
| 2025-07-17 | Kintz Samuel PRESIDENT AND CEO | Sale 10b5-1 | −3,663 | $23.37 | $86K | 940,392 |
| 2025-07-10 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Option exercise 10b5-1 | +1,000 | $2.48 | $2K | 24,000 |
Page 9 of 37 · 724 trades